Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression
- PMID: 20386568
- PMCID: PMC2927798
- DOI: 10.1038/mp.2010.44
Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression
Abstract
Several studies have proposed that brain glutamate signaling abnormalities and glial pathology have a role in the etiology of major depressive disorder (MDD). These conclusions were primarily drawn from post-mortem studies in which forebrain brain regions were examined. The locus coeruleus (LC) is the primary source of extensive noradrenergic innervation of the forebrain and as such exerts a powerful regulatory role over cognitive and affective functions, which are dysregulated in MDD. Furthermore, altered noradrenergic neurotransmission is associated with depressive symptoms and is thought to have a role in the pathophysiology of MDD. In the present study we used laser-capture microdissection (LCM) to selectively harvest LC tissue from post-mortem brains of MDD patients, patients with bipolar disorder (BPD) and from psychiatrically normal subjects. Using microarray technology we examined global patterns of gene expression. Differential mRNA expression of select candidate genes was then interrogated using quantitative real-time PCR (qPCR) and in situ hybridization (ISH). Our findings reveal multiple signaling pathway alterations in the LC of MDD but not BPD subjects. These include glutamate signaling genes, SLC1A2, SLC1A3 and GLUL, growth factor genes FGFR3 and TrkB, and several genes exclusively expressed in astroglia. Our data extend previous findings of altered glutamate, astroglial and growth factor functions in MDD for the first time to the brainstem. These findings indicate that such alterations: (1) are unique to MDD and distinguishable from BPD, and (2) affect multiple brain regions, suggesting a whole-brain dysregulation of such functions.
Figures

Similar articles
-
Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression.Int J Neuropsychopharmacol. 2014 Oct;17(10):1569-78. doi: 10.1017/S1461145714000662. Epub 2014 Jun 13. Int J Neuropsychopharmacol. 2014. PMID: 24925192
-
Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder.J Psychiatry Neurosci. 2013 Jul;38(4):276-84. doi: 10.1503/jpn.120110. J Psychiatry Neurosci. 2013. PMID: 23415275 Free PMC article.
-
Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder.J Psychiatr Res. 2013 Sep;47(9):1150-6. doi: 10.1016/j.jpsychires.2013.04.007. Epub 2013 May 24. J Psychiatr Res. 2013. PMID: 23706640
-
Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system.J Neurochem. 2016 Oct;139 Suppl 2:154-178. doi: 10.1111/jnc.13447. Epub 2016 Mar 10. J Neurochem. 2016. PMID: 26968403 Review.
-
Glial glutamate transporters: new actors in brain signaling.IUBMB Life. 2011 Oct;63(10):816-23. doi: 10.1002/iub.536. Epub 2011 Sep 7. IUBMB Life. 2011. PMID: 21901813 Review.
Cited by
-
Measuring anxiety disorder in bipolar disorder using EVestG: broad impact of medication groups.Front Neurol. 2024 Jan 16;14:1303287. doi: 10.3389/fneur.2023.1303287. eCollection 2023. Front Neurol. 2024. PMID: 38292032 Free PMC article.
-
General Pathophysiology of Astroglia.Adv Exp Med Biol. 2019;1175:149-179. doi: 10.1007/978-981-13-9913-8_7. Adv Exp Med Biol. 2019. PMID: 31583588 Free PMC article. Review.
-
Altered choroid plexus gene expression in major depressive disorder.Front Hum Neurosci. 2014 Apr 22;8:238. doi: 10.3389/fnhum.2014.00238. eCollection 2014. Front Hum Neurosci. 2014. PMID: 24795602 Free PMC article.
-
How Electroconvulsive Therapy Works?: Understanding the Neurobiological Mechanisms.Clin Psychopharmacol Neurosci. 2017 Aug 31;15(3):210-221. doi: 10.9758/cpn.2017.15.3.210. Clin Psychopharmacol Neurosci. 2017. PMID: 28783929 Free PMC article. Review.
-
Overview of glutamatergic neurotransmission in the nervous system.Pharmacol Biochem Behav. 2012 Feb;100(4):656-64. doi: 10.1016/j.pbb.2011.08.008. Epub 2011 Aug 26. Pharmacol Biochem Behav. 2012. PMID: 21889952 Free PMC article. Review.
References
-
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. - PubMed
-
- Rivelli S, Jiang W. Depression and ischemic heart disease: what have we learned from clinical trials? Curr Opin Cardiol. 2007;22(4):286–291. - PubMed
-
- Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy. 1997;17(1):10–21. - PubMed
-
- Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry. 2000;47(9):818–829. - PubMed
-
- Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry. 1999;56(5):395–403. - PubMed